Related Experiment Videos
A model for management of sublingual immunotherapy
F Frati1, L Sensi, V Di Rienzo
1University of Perugia, Department of Obstetric, Gynaecologic and Paediatric Sciences, Perugia, Italy.
European Annals of Allergy and Clinical Immunology
|April 4, 2003
Summary
High-dose sublingual immunotherapy (SLIT) is well-tolerated in children, with most side effects being mild oral or gastrointestinal reactions. A structured management approach effectively resolved these issues, allowing nearly all patients to reach the maintenance dose.
Area of Science:
- Allergy and Immunology
- Pediatric Medicine
- Immunotherapy
Background:
- Sublingual immunotherapy (SLIT) is a common treatment for allergic diseases.
- High-dose SLIT can cause local side effects, primarily affecting the oral and gastrointestinal mucosa.
- These side effects, if unmanaged, may lead to treatment discontinuation.
Purpose of the Study:
- To introduce and evaluate a management method for side effects associated with high-dose SLIT in children.
- To assess the efficacy of the proposed management strategy in enabling patients to reach and maintain the therapeutic dose.
Main Methods:
- A cohort of 200 children received high-dose SLIT using Staloral 300.
- Treatment involved a standardized schedule and dosage regimen.
- Side effect management followed specific flowcharts, adjusting dose, regimen, or administration based on reaction type (oral, gastrointestinal, respiratory).
Main Results:
- 155 out of 200 children (77.5%) experienced no adverse reactions.
- 45 children (22.5%) reported side effects, including oral itching/burning (20), gastrointestinal symptoms (15), and rhinitis (10).
- No systemic reactions were observed, and all reported side effects were successfully managed, with only one patient discontinuing treatment.
Conclusions:
- High-dose SLIT is generally well-tolerated in pediatric populations.
- A systematic management approach effectively addresses common side effects like oral itching and gastrointestinal disturbances.
- Proper management facilitates achieving the maintenance dose in the vast majority of patients undergoing SLIT.